Introduction Quantitative systems pharmacology (QSP) models describe the clinical pharmacological properties of a drug. They are typically described as systems of linear mass-balance and nonlinear mass-action of drugs. One of the purposes of QSP models is to simulate potential outcomes from virtual clinical trials. This approach is predicated on generating virtual populations of patients (a […]
Steve Duffull
- PAGANZ Inc Society Member
- University of Otago
Author Archive | Steve Duffull
PAGANZ Workshop: CellML and OpenCOR
Over the past 10 year quantitative systems pharmacology has become an integral part of pharmacometrics. While the models and methods used in a QSP framework are novel to pharmacometricians they have been well established in the disciplines of systems biology and bioengineering. Software (e.g. CellML, SBML, …) for specifying models and enabling simulations from models […]
Dose banding- weighing up benefits vs risks
Background: Dose banding is the allocation of patients into a pre-specified dose group based on the patient’s value of a covariate and is commonly recommended in drug labels. The simplest form of dose banding assigns all patients to receive the same dose irrespective of their characteristics. The corollary to “one dose fits all” is where […]
An approach to evaluating mass and energy balance of pharmacokinetic systems using bond graph theory
Introduction: Quantitative systems pharmacology models are used in PKPD and pharmacometrics to describe the effects of drugs as modulators of system behaviour. In most cases the systems that are described in these models can be constructed of modular units that can be assembled en-masse to create the overall system. An example of a modular component […]
Development and application of a pharmacokinetic model for the glycation of albumin
Background Glycated haemoglobin, HbA1c, is used commonly as a marker for glycaemic control. In patients with chronic kidney disease (CKD) red blood cells (RBCs) are removed faster from the circulation, giving less time for glycation of haemoglobin to occur [1]. Thus, HbA1c concentrations are falsely lowered in these patients. Glycated albumin (GA) has been suggested […]
Evaluation of an optimal design for examining melphalan pharmacokinetics in patients with multiple myeloma
Background: The optimal design of population pharmacokinetics allows parameter estimation with minimum variance and reduced cost by identifying (1) the minimum number of blood samples required from each subject, (2) the optimal blood sampling times and (3) the minimum number of subjects required. Aim: To evaluate the results of an optimal design experiment that was […]